SPI Pharma and Inimmune Partner on Adjuvant Systems

Leading provider of adjuvant systems and biopharmaceutical excipients, SPI Pharma Inc., has teamed up with Inimmune Corp., a biotechnology business specialising in innate immune modulators, to create and market cutting-edge adjuvant systems for vaccinations. This partnership brings together SPI Pharma's manufacturing and international marketing skills with Inimmune's adjuvant formulation and immunotherapy knowledge.Adjuvant systems are essential for vaccine development because they improve the immune response and effectiveness of vaccines. Through the cooperation, important unmet needs will be addressed and the availability of these technologies to healthcare practitioners and patients worldwide will be accelerated. The alliance seeks to secure a reliable supply and broad access to innovative adjuvant systems.

The excellent synergy between SPI Pharma's robust commercial infrastructure and Inimmune's commitment to advance immunological research was emphasised by John McInerney, Vice President of Commercial at SPI Pharma.The CEO of Inimmune, Alan Joslyn, Ph.D., expressed enthusiasm about the partnership and emphasised their mutual dedication to innovation in public health.